ArticleInternational journal of cancer2025

Antitumor efficacy of intermittent low-dose erlotinib plus sulindac via MHC upregulation and remodeling of the immune cell niche.

Chakrapani Tripathi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.